Figure 5
ILT2 expression by CD4+ T cell populations in non-responder and responder melanoma patients before and after rV-B7.1 treatment. (A- D) Frequency of peripheral blood cells expressing (A) FoxP3 among CD4+ T cells and ILT2 among (B) CD4+ T cells, and (C) CD4+FoxP3+ T cells was evaluated by flow cytometry in non-responder (n = 5) and responder (n = 4) metastatic melanoma patients before (pre) and after (post) intra-tumoral rV-B7.1 treatment.